A new kind of cancer treatment is emerging—one that turns the patient’s own body into a drug factory. Here's what you need to ...

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the ...

The authorisation comes three months after the MHRA approved Johnson & Johnson’s Lazcluze (lazertinib), which is also ...

BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeedin, BIOS ...

Lung cancer is a dangerous disease that ranks first in cancer mortality in Korea, and there are few initial symptoms, making ...

Panelists discuss how promising ongoing and upcoming clinical trials may reshape sequencing strategies in ALK+ non–small cell lung cancer (NSCLC).

How Targeted Approaches Are Changing Management of Advanced EGFR-Mutant Lung Cancer and Pavingthe Way for ...

NCoR1/RARα interaction was identified as a target for selective chaperone-mediated autophagy (CMA) inhibition in lung cancer.

A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the ...

Concentra will acquire the firm for $.36 per share in cash in a deal that was approved by Elevation Oncology's board.